Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542212 | 0.89 | F10 (0.49) | F10 | |
| SCHEMBL3556721 | 0.89 | F10 (0.47) | F10MEN1MAPTKMT2AKDR | |
| SCHEMBL3557809 | 0.84 | F10 (0.53) | F10MAPTALDH1A1KDM4ERXFP1 | |
| SCHEMBL3550961 | 0.84 | F10 (0.53) | F10MAPTALDH1A1KDM4ERXFP1 | |
| SCHEMBL3554783 | 0.83 | F10 (0.53) | F10MTOR | |
| SCHEMBL3549307 | 0.83 | F10 (0.53) | F10MTOR | |
| SCHEMBL13436081 | 0.78 | F10 (0.59) | F10 | |
| SCHEMBL3542214 | 0.77 | F10 (0.51) | F10 | |
| SCHEMBL5627481 | 0.76 | F10 (0.55) | F10MEN1MAPTKMT2AKDR | |
| SCHEMBL5626752 | 0.76 | F10 (0.55) | F10MEN1MAPTKMT2AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678917-B2 | Factor Xa inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070049587-A1 | Factor Xa inhibitors | HOFFMANN-LA ROCHE INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049587-A1 | Factor Xa inhibitors | F12, F11, F10 | F10 3/4885MEN1 680/4885MAPT 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.